ChemPartner

ChemPartner is a contract research and contract development and manufacturing organization (CRO/CDMO) serving biotechnology and pharmaceutical companies. Founded in Shanghai in 2003, it began as a discovery-chemistry-focused organization and has developed into an integrated preclinical services partner. The company describes its work as helping biopharma teams advance programs from early discovery through IND-enabling development, connecting chemistry, biology, pharmacology, DMPK, toxicology, and CMC support. Its service portfolio spans small-molecule discovery chemistry and drug design, biologics discovery, and associated preclinical research and development. Chemistry capabilities include target and hit identification, hit-to-lead work, lead optimization, preclinical candidate selection, and IND-enabling support. The company describes a design–make–test–analyze workflow and lists computational and AI-enabled capabilities such as virtual screening, de novo design, scaffold hopping, ADMET prediction, free-energy perturbation, and retrosynthesis. Its biologics services include protein science, antibody discovery and engineering, structural biology, developability assessment, and support for monoclonal antibodies, bispecific antibodies, ADCs and other conjugate formats. ChemPartner says it operates across North America, Europe, and Asia and has more than 2,000 scientists. Its website identifies clients ranging from emerging biotechnology companies to global pharmaceutical organizations, and its chemistry page says it supports programs from emerging biotech through Top-20 multinational pharmaceutical companies. The company says it was listed on the Shenzhen Stock Exchange in 2010 under stock code 300149. Current headquarters, founder, parent company, and ownership details are not established by the supplied evidence.

ChemPartner was founded in Shanghai, China, in 2003. According to the company’s account, it began as a discovery-chemistry-focused organization, with the ambition of becoming a scientific partner for the evolving needs of drug discovery and development. Its subsequent development broadened its service scope beyond chemistry into an integrated preclinical CRO and CDMO model, with services spanning discovery, translational research, preclinical development, and manufacturing. The company’s listed milestones begin with its founding in Shanghai in 2003. In 2009, it says it expanded operations into Europe. In 2010, it says it listed on the Shenzhen Stock Exchange under stock code 300149. In 2014, it established a US site in San Francisco. The About page also displays a 2015–2020 expansion period, but the supplied text does not provide further details, so no specific expansion event is attributed to those years here. ChemPartner describes its present-day business as an integrated set of scientific services for biopharmaceutical innovators. Its offering connects discovery chemistry, biology, pharmacology, DMPK, toxicology, and CMC support, with programs intended to progress from early discovery toward IND-enabling development. Its chemistry services cover target and hit identification, hit-to-lead, lead optimization, preclinical candidate generation, and development of IND-ready data packages. The company also describes AI-enabled drug discovery capabilities and an XDrug.AI platform. Its biologics discovery work includes protein science, assay development, antibody discovery, lead optimization, structural biology, and developability assessment. The formats and programs named on its website include monoclonal and bispecific antibodies, ADCs, XDC and multispecific conjugates, TCR-mimic antibodies, and engineered antibody fragments. The company says downstream development, GMP manufacturing, and regulatory support may also be available as programs advance. ChemPartner reports operations across North America, Europe, and Asia, with more than 2,000 scientists. It presents itself as serving both emerging biotechnology companies and global pharmaceutical organizations. The company’s website characterizes its history as more than two decades of scientific partnership. Current headquarters, founder, parent company, and ownership are not established by the supplied evidence.

• 2014

  Established a San Francisco site

• 2010

  Listed on the Shenzhen Stock Exchange

• 2009

  Expanded operations into Europe

• 2003

  Founded in Shanghai, China

A global, integrated preclinical CRO/CDMO partner combining scientific services across drug discovery, preclinical development, and related CMC support.

• Integrated discovery chemistry services

  Services span hit identification, hit-to-lead, lead optimization, preclinical candidate generation, and IND-enabling support.

• Biologics discovery services

  The platform includes protein science, antibody discovery and engineering, structural biology, and developability assessment for multiple biologic formats.

• XDrug.AI

  An AI drug discovery platform identified on the ChemPartner homepage.

• 2023

  Source

Read more

1. 1Global CRO for Preclinical Drug Development | ChemPartnerchempartner.com
2. 2Global CRO/CDMO Partner for Biopharma | ChemPartnerchempartner.com
3. 3Discovery Chemistry Services & Drug Design | ChemPartnerchempartner.com
4. 4Biologics Discovery Services & Platform | ChemPartner CROchempartner.com
5. 5商誉减值测试不合规、会计差错更正，两年两收警示函csrc.gov.cn
6. 6商誉减值测试不合规、会计差错更正，两年两收警示函csrc.gov.cn
7. 7商誉减值测试不合规、会计差错更正，两年两收警示函dianzibao.cb.com.cn